Rangering i aksjer
#28207
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
Aksjekurs
$0.4
Sist synkronisert: 2026-10-02
Handel Cell Source, Inc. (CLCS)
Pris CLCS pris med markedsverdi på B
Markedsverdi av Cell Source, Inc.(CLCS)
Markedsverdi: $27.18M
Per October 2026 har Cell Source, Inc. en markedsverdi på $27.18M. Dette gjør Cell Source, Inc. til det 28207th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Cell Source, Inc. fra 2014 til 2026
CLCS sammenlignet med topp 5 mest populære stocks
| Pris på CLCS |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.807T
|
+21,367,012.68%
|
|
|
|
|
$4.891T
|
+17,994,900.12%
|
|
|
|
|
$4.177T
|
+15,369,855.18%
|
|
|
|
|
$3.919T
|
+14,417,670.59%
|
|
|
|
|
$2.724T
|
+10,022,661.63%
|
